Hrouda D, Dalgleish A G
Department of Oncology, St George's Hospital Medical School, London, UK.
Gene Ther. 1996 Oct;3(10):845-52.
Prostate cancer is one of the leading causes of cancer deaths in the Western world and current therapies are of limited efficacy in advanced disease. Both ex vivo and in vivo gene therapy strategies offer exciting new possible approaches to the management of this disease. Ex vivo gene therapy involving interleukin-2 or granulocyte-macrophage colony-stimulating factor transduced whole tumour cell vaccines has shown great promise in animal models. The feasibility of in vivo corrective gene therapy involving the replacement of mutant tumour suppressor genes, antisense strategies and the insertion of suicide genes has been demonstrated in preclinical models. Several of these therapies are now entering phase I/II studies in patients with prostate cancer.
前列腺癌是西方世界癌症死亡的主要原因之一，目前的治疗方法对晚期疾病的疗效有限。离体和体内基因治疗策略都为这种疾病的治疗提供了令人兴奋的新方法。涉及白细胞介素-2或粒细胞-巨噬细胞集落刺激因子转导的全肿瘤细胞疫苗的离体基因治疗在动物模型中显示出巨大的前景。在临床前模型中已经证明了涉及替换突变肿瘤抑制基因、反义策略和插入自杀基因的体内纠正基因治疗的可行性。其中几种治疗方法目前正在前列腺癌患者中进入I/II期研究。
